Plasma Limitrin Level as a Diagnostic Biomarker and Predictor of Recurrence for Doubleseronegative Idiopathic Optic Neuritis

To evaluate the clinical relevance of the plasma limitrin level in patients with double-seronegative idiopathic optic neuritis (DS-ION).

290 Plasma Limitrin Level as a Diagnostic Biomarker and Predictor of Recurrence for Double-seronegative Idiopathic Optic Neuritis Bo Young Chun 1 1 Kyungpook National University School of Medicine Introduction: To evaluate the clinical relevance of the plasma limitrin level in patients with double-seronegative idiopathic optic neuritis (DS-ION). Methods: Peripheral blood samples were collected from 27 patients with DS-ION and 30 healthy controls. Plasma limitrin levels were measured using an enzyme-linked immunosorbent assay. The correlation between plasma limitrin levels and recurrence was analyzed. A receiver operating characteristic (ROC) curve was constructed to assess the ability of plasma limitrin levels to predict recurrent ION. Results: The mean plasma limitrin level was significantly higher in patients with DS-ION (1.94 vs. 0.74 ng/mL, p = 0.0007). Plasma limitrin level and visual acuity at diagnosis were significantly correlated (r = 0.42, p = 0.029). The area under the ROC curve of plasma limitrin level was 0.765 (p = 0.0065). The cut-off plasma limitrin level of 1.37 ng/mL predicted recurrence with a sensitivity and specificity of 70.0% and 76.5%, respectively. Patients with plasma limitrin level > 1.37 ng/mL showed significantly higher recurrence rates (63.6% vs. 18.8%) and shorter intervals (median interval 4 vs. 51 months) than patients with plasma limitrin level ≤ 1.37 ng/mL. Conclusions: Patients with DS-ION demonstrated significantly higher plasma limitrin levels than controls, and those with plasma limitrin level >1.37 ng/mL demonstrated worse vision at diagnosis and higher recurrence rates. Thus, plasma limitrin level could serve as diagnostic biomarker and predictor of recurrence for DS-ION. References: None provided. Keywords: Optic neuritis, Demeylinating disease Financial Disclosures: The authors had no disclosures. Grant Support: None. Contact Information: Bo Young Chun, [e-mail] 448 | North American Neuro-Ophthalmology Society